Table 3.
Pooled incidence of immune-related adverse events (irAEs) in patients receiving pembrolizumab-based regimens.
| System/adverse event | No. of studies (k) | Events/total | Pooled rate (%) | 95% CI | I² (%) | p (Q test) |
|---|---|---|---|---|---|---|
| Gastrointestinal | ||||||
| Colitis | 2 | 37/1226 | 3 | 2.2–4.2 | 0 | 0.423 |
| Pancreatitis | 2 | 9/1226 | 0.8 | 0.2–2.6 | 69.2 | 0.071 |
| Skin | ||||||
| Severe skin reactions | 2 | 31/1226 | 2.6 | 1.6–4.3 | 52 | 0.149 |
| Hepatic | ||||||
| Hepatitis | 2 | 17/1226 | 1.4 | 0.9–2.3 | 0 | 0.342 |
| Endocrine | ||||||
| Hypothyroidism | 2 | 248/1226 | 21.4 | 10.9–37.7 | 96.9 | <0.001 |
| Hyperthyroidism | 2 | 77/1226 | 6.4 | 4.8–8.5 | 40.5 | 0.195 |
| Adrenal insufficiency | 2 | 23/1226 | 2 | 0.9–4.4 | 75.4 | 0.044 |
| Thyroiditis | 2 | 11/1226 | 0.9 | 0.4–2.0 | 29.6 | 0.233 |
| Hypophysitis | 2 | 8/1226 | 0.7 | 0.2–2.0 | 55.2 | 0.135 |
| Type1 diabetes | 2 | 7/1226 | 0.6 | 0.3–1.2 | 0 | 0.684 |
| Respiratory | ||||||
| Pneumonitis | 2 | 40/1226 | 3.3 | 2.4–4.4 | 0 | 0.838 |
| Renal | ||||||
| Nephritis | 2 | 9/1226 | 0.8 | 0.4–1.7 | 30.2 | 0.231 |
| Cardiovascular | ||||||
| Vasculitis | 2 | 5/1226 | 0.5 | 0.2–1.2 | 14 | 0.281 |
| Myocarditis | 2 | 2/1226 | 0.2 | 0.0–1.5 | 35.4 | 0.214 |
| Musculoskeletal | ||||||
| Myositis | 2 | 2/1226 | 0.2 | 0.0–0.7 | 0 | 0.683 |
| Overall_irAE | ||||||
| AnyGrade irAE n | 3 | 529/1730 | 31.1 | 19.4–45.8 | 96.9 | <0.001 |
| Grade35 irAE n | 3 | 135/1730 | 7.8 | 5.8–10.4 | 65.2 | 0.056 |